BostonGene's Multiomic AI Platform Uncovers Therapeutic Targets in Invasive Lobular Carcinoma, Wins GRASP Advocate Choice Award at ASCO 2025
BUSINESS WIRE)-- BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received the GRASP Advocate Choice Award. The poster, titled ' Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes,' was presented by Jason Mouabbi, MD, of The University of Texas MD Anderson Cancer Center, on June 2, 2025.
"It also highlights the role of multiomic data in informing trial design, optimizing patient selection, and accelerating the development of precision oncology therapeutics.'
In collaboration with MD Anderson, BostonGene applied its proprietary multiomic AI platform to profiles of over 600 patients, uncovering distinct histologic and molecular features of invasive lobular carcinoma (ILC)—a breast cancer subtype for which treatment decisions are often inferred from other subtypes. The study revealed previously under-characterized macroscale genomic alterations and biologic mechanisms, highlighting opportunities for precision-targeted therapies and novel drug development strategies tailored to ILC. These insights demonstrate BostonGene's unique capabilities to uncover disease-specific targets and enable data-driven decisions in clinical development.
The GRASP (Guiding Researchers and Advocates to Scientific Partnerships) Advocate Choice Award recognizes research that is both scientifically meaningful and impactful to the patient community, as determined by cancer advocates. GRASP is a nonprofit, patient-led initiative that brings together researchers, clinicians and patients to foster scientific collaboration and accelerate innovation in cancer care. The 2025 GRASP event is held in conjunction with the ASCO Annual Meeting on June 11–12.
'We're incredibly proud to be recognized by the GRASP advocate community, which underscores the strength of our collaboration with MD Anderson and the real-world impact of BostonGene's AI-powered analytics,' said Nathan Fowler, MD, Chief Medical Officer at BostonGene. 'This study illustrates how our platform can uncover clinically actionable genomic insights and help reshape treatment paradigms for historically underserved cancer subtypes like ILC. It also highlights the role of multiomic data in informing trial design, optimizing patient selection, and accelerating the development of precision oncology therapeutics.'
About BostonGene Corporation
BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients. For more information, visit www.BostonGene.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Securonix Acquires ThreatQuotient to Deliver Industry's Broadest and Deepest Threat Detection Investigation and Response
PLANO, Texas--(BUSINESS WIRE)--Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of ThreatQuotient, a four-time leader in threat intelligence based on QKS Group Spark Matrix report and the force behind ThreatQ, the most innovative external threat intelligence platform. This combination will create a comprehensive, modular, and fully integrated AI-driven platform for threat detection, investigation, and response (TDIR), leveraging advanced analytics and insights across both internal and external threats. This acquisition accelerates the modernization of security operations by uniting internal and external threat intelligence with real-time analytics and agentic AI. Unlike external threat intelligence bolt-on solutions with disconnected management interfaces, the integrated platform from Securonix and ThreatQuotient will deliver unified visibility, faster response, and greater operational clarity. "Bringing threat intelligence management and SIEM together in a unified platform is a game changer. We've already seen the value of deeply enriched advanced analytics and detection in our Securonix SIEM environment—but coupling that with integrated threat curation, prioritization, and response should help customers move even faster. It means fewer swivel-chair investigations, more accurate triage, and greater confidence that security analysts are working with the most relevant threats. This kind of integration has the potential to accelerate the ability to detect, respond, and stay ahead," said Marcel Jonker, Director of Cybersecurity Operations at Cambia Health Systems. The integration of Securonix and ThreatQuotient promises to deliver up to a 70% reduction in Mean Time to Respond (MTTR), enabling security teams to detect, investigate, and remediate threats significantly faster. By combining curated threat intelligence with AI-driven automation, the solution will deliver exponential improvements in filtering out false positives, enriching alerts with actionable context, and automating historical threat sweeps and incident response. This reduces alert overload, speeds up root cause analysis, and minimizes manual handoffs—cutting investigation time from hours to minutes and enabling automated containment before threats escalate. 'Security teams are drowning in noise and struggling to keep up with evolving threats,' said Kash Shaikh, CEO and President of Securonix. 'This acquisition brings together Securonix's Agentic AI-driven Platform with ThreatQuotient's deep threat intelligence to deliver clarity, speed, and automated workflows to our customers, reducing false positives by up to 90%. Together, we're building the modern SOC Platform—proactive, intelligent, and built for what's next.' Kash added, 'Securonix and ThreatQuotient bring together complementary strengths—deep innovation across internal and external threat domains, and a shared commitment to innovation and customer service. Both companies serve enterprise and government customers as well as managed security service providers (MSSPs), and we're excited to welcome the talented ThreatQuotient team and their customers to Securonix.' Purpose-Built for Analysts. Proven Against Real-World Threats. ThreatQuotient's Threat Intelligence Platform (TIP) strength lies in delivering curated, contextualized threat intelligence that drives smart, timely decisions. When combined with Securonix's EON Agentic AI-based SIEM, SOAR, UEBA and Data Pipeline Manager, customers can accelerate their migration from reactive threat hunting-based defense to proactive, real-time, behavior-driven, open-agentic security operations. With this integration, Securonix customers and partners will enjoy the following benefits: Gain clear visibility: Integrate deep enriched real-time analytics from Securonix with curated external intelligence from ThreatQuotient to create a single, high-context stream of alerts. Eliminate blind spots and accelerate threat identification with confidence. Stay ahead of risk: Auto-enrich Indicator of compromise (IoCs) and preemptively respond to repeat attacks, blocking 90 percent before they start. Act smarter: Automate repetitive tasks, reduce false positives, and streamline investigations. Teams can stay focused on high-priority threats and reduce time spent on manual triage. Deploy your way: Continue to use ThreatQ as a standalone threat intelligence platform or as part of the fully integrated Securonix solution. Deploy on-premise or SaaS in a way that fits the current architecture and scales with needs. Accelerated Roadmap: Combined R&D synergies will accelerate upcoming roadmap innovations, including Agentic AI and ThreatQuotient's innovation priorities. With this acquisition, ThreatQuotient customers and partners will enjoy the following benefits: Increased Scale: ThreatQ customers can take advantage of Securonix's global R&D scale and GTM reach, including access to Securonix's Threat Labs Intelligence. Deeper Integrations: Gain access to an enriched roadmap and integration between Securonix's best-in-class SIEM, SOAR, and UEBA portfolio and ThreatQ, including extension of Agentic AI advancements. Continued Focus: Zero interruption of their existing service, as ThreatQuotient will continue to operate as a standalone offering, with no disruption to existing roadmap and workflows. 'Enterprises, government institutions and managed security service providers rely on ThreatQuotient to protect their mission critical businesses. Joining Securonix marks a powerful new chapter for ThreatQuotient. By uniting our strengths, we can accelerate innovation, expand our reach, and deliver greater value to our customers. I'm proud of what we've built and excited for what's ahead,' said John Czupak, CEO of ThreatQuotient. BTIG, LLC served as exclusive financial advisor, and King & Spalding LLP served as legal advisor to ThreatQuotient. Vinson & Elkins LLP served as legal advisor to Securonix. About Securonix Securonix is leading the transformation of cybersecurity with the industry's first Unified Defense SIEM powered by agentic AI, purpose-built to decide and act across the threat lifecycle with a human-in-the-loop philosophy. Built for scale, precision, and speed, our cloud-native platform empowers global enterprises to shift from reactive security to proactive, autonomous operations. Recognized as a Leader in the Gartner® Magic Quadrant™ for SIEM and a Customers' Choice by Gartner Peer Insights™, Securonix is driving the next era of intelligent, autonomous security operations. Learn more at About ThreatQuotient ThreatQuotient improves security operations by fusing disparate data sources, tools, and teams to accelerate threat detection, investigation, and response (TDIR). ThreatQ is the first purpose-built, data-driven threat intelligence platform that helps teams prioritize, automate, and collaborate on security incidents; enables more focused decision-making; and maximizes limited resources by integrating existing processes and technologies into a unified workspace. The result is reduced noise, clear priority threats, and the ability to automate processes with high-fidelity data. ThreatQuotient's leading integration marketplace, data management, orchestration, and automation capabilities support multiple use cases including threat intelligence management and sharing, incident response, threat hunting, spear phishing, alert triage, and vulnerability management. For more information, visit
Business Wire
3 hours ago
- Business Wire
Specialities Inc. Introduces Hollandic
MILLINGTON, N.J.--(BUSINESS WIRE)-- Hollandic is how we say Gouda cheese! We are thrilled to introduce Hollandic, our exquisite Gouda cheese that brings a slice of the Netherlands to your table! Revered as one of the world's oldest cheeses, Hollandic is crafted from premium cow's milk, resulting in a semi-hard cheese that is rich in flavor and boasts a wonderfully creamy texture. Dutch Gouda stands out for its exceptional quality and rich heritage, making it a beloved choice for cheese aficionados around the globe. Our Hollandic Gouda selection features a delightful variety, ranging from young and mild to intensely aged, each showcasing its distinct taste and character. Perfect on its own or as the star of a vibrant charcuterie board, Hollandic Gouda is the ideal addition to your culinary adventures! Since 1991, Specialities Inc. has been at the forefront of importing, distributing, and elevating specialty food products across U.S. Deli and Specialty Markets, along with select food service distributors. Our 'Best of Class' offerings originate from both domestic and international artisans. Please join us on June 28-30, 2025, at the New York Fancy Food Show Booth 468 to learn more about these all-natural and innovative products.
Yahoo
3 hours ago
- Yahoo
Specialities Inc. Introduces Hollandic
MILLINGTON, N.J., June 14, 2025--(BUSINESS WIRE)--Hollandic is how we say Gouda cheese! We are thrilled to introduce Hollandic, our exquisite Gouda cheese that brings a slice of the Netherlands to your table! Revered as one of the world's oldest cheeses, Hollandic is crafted from premium cow's milk, resulting in a semi-hard cheese that is rich in flavor and boasts a wonderfully creamy texture. Dutch Gouda stands out for its exceptional quality and rich heritage, making it a beloved choice for cheese aficionados around the globe. Our Hollandic Gouda selection features a delightful variety, ranging from young and mild to intensely aged, each showcasing its distinct taste and character. Perfect on its own or as the star of a vibrant charcuterie board, Hollandic Gouda is the ideal addition to your culinary adventures! Since 1991, Specialities Inc. has been at the forefront of importing, distributing, and elevating specialty food products across U.S. Deli and Specialty Markets, along with select food service distributors. Our "Best of Class" offerings originate from both domestic and international artisans. Please join us on June 28-30, 2025, at the New York Fancy Food Show Booth 468 to learn more about these all-natural and innovative products. View source version on Contacts Ron Schinbeckler, Specialities Inc. (908) 294-3200, (908) 647.6485fromo1@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
